In addition, another aim of this study is to investigate whether febuxostat, a potent and selective XOR inhibitor, has a beneficial role in mitigating GEC injury through this novel mechanism and could suggest its potential as a therapeutic candidate for preventing GEC injury in DKD. The gene discussed is XDH; the disease is diabetic kidney disease.